MEDIA GENERAL INC Form 8-K March 21, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 21, 2014

MEDIA GENERAL, INC.

(Exact name of registrant as specified in its charter)

Commonwealth of Virginia 1-6383 54-0850433

(State or other jurisdiction (Commission (I.R.S. Employer

of incorporation) File Number) Identification Number)

333 E. Franklin St.

Richmond, VA 23219

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (804) 887-5000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

Merger Agreement

On March 21, 2014, Media General, Inc., (the "Company") issued a joint press release with LIN Media LLC ("LIN Media") announcing the entry into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, certain of its subsidiaries, and LIN Media providing for a strategic business combination transaction between the Company and LIN Media (the "Combination"). The Company has provided additional information regarding the Combination in a webcast with investors.

A copy of the joint press release is attached hereto as Exhibit 99.1, the investor presentation used in connection with the Company's webcast is attached hereto as Exhibit 99.2, and each is incorporated herein in their entirety by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Joint Press Release of Media General, Inc. and LIN Media LLC dated March 21, 2014

99.2	Investor
00.2	Presentation,
99.2	dated March
	21, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 21, 2014

MEDIA GENERAL, INC.

By: /s/ James F. Woodward Name: James F. Woodward Title: Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No. Description

Joint Press Release of Media General, Inc. and LIN Media LLC
Media LLC dated March
21, 2014

	Investor
00.2	Presentation,
99.2	dated March
	21, 2014

0em; text-indent:-1.00em">ASSETS

Restricted Cash

\$6,271 \$

Total investments, at value (cost of \$166,513 and \$0, respectively)

165,445 226,997

Total assets

\$171,716 \$226,997

LIABILITIES

Asset-Backed Notes

\$89,557 \$129,300

Total liabilities

\$89,557 \$129,300

F-4

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

		the Years End December 31,	led
	2013	2012	2011
Investment income:			
Interest Income			
Non-Control/Non-Affiliate investments	\$ 121,302	\$ 85,258	\$ 69,552
Affiliate investments	2,369	2,345	
Control investments			794
Total interest income	123,671	87,603	70,346
Fees			
Non-Control/Non-Affiliate investments	16,016	9,897	9,400
Affiliate investments	26	20	14
Control investments			95
Total fees	16,042	9,917	9,509
T-6-1 :	120 712	07.520	70.955
Total investment income Operating expenses:	139,713	97,520	79,855
Interest	30,334	19,835	13,252
Loan fees	4,807	3,917	2,635
General and administrative	9,354	8,108	7,992
Employee Compensation:	7,554	0,100	1,772
Compensation and benefits	16,179	13,326	13,260
Stock-based compensation	5,974	4,227	3,128
Total employee compensation	22,153	17,553	16,388
Total operating expenses	66.648	49,413	40,267
	00,010	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	.0,207
Net investment income	73,065	48,107	39,588
Net realized gain on investments	15,005	40,107	57,500
Non-Control/Non-Affiliate investments	14,836	3,168	2,741
Total net realized gain on investments	14,836	3,168	2,741
Net increase (decrease) in unrealized appreciation on investments			
Non-Control/Non-Affiliate investments	12,370	(2,448)	(3,976)
Affiliate investments	(825)	(2,068)	3,425
Control investments			5,158
Total net unrealized appreciation (depreciation) on investments	11,545	(4,516)	4,607
Total net realized and unrealized gain (loss)	26,381	(1,348)	7,348
Net increase in net assets resulting from operations	\$ 99,446	\$ 46,759	\$ 46,936

Net investment income before investment gains and losses per common share:					
Basic	\$ 1.22	\$	0.96	\$	0.91
Change in net assets per common share:					
Basic	\$ 1.67	\$	0.93	\$	1.08
Diluted	\$ 1.63	\$	0.93	\$	1.07
Weighted average shares outstanding					
Basic	58,838	4	9,068	4	42,988
Diluted	60,292	4	9,156		43,299

See notes to consolidated financial statements.

F-5

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

(dollars and shares in thousands)

	Commo	on Sto	ock							listributed net vestment	Pre	ovision	
	Shares	Par	Value	Capital in excess of par value	Ap	nrealized preciation on vestments	F (L	cumulated Realized Gains osses) on vestments	i (Dis in in	ncome/ atributions excess of vestment ncome)	Ta Inv	for acome axes on estment Gains	Net Assets
Balance at December 31, 2010	43,444	\$	43	\$ 477,549	\$	(8,038)	\$	(51,033)	\$	(5,648)	\$	(342)	\$ 412,531
Net increase in net assets resulting from												, í	
operations						4,607		2,741		39,588			46,936
Issuance of common stock	188		1	981									982
Issuance of common stock under restricted													
stock plan	140												
Issuance of common stock as stock dividend	167			1,649									1,649
Retired shares from net issuance	(86)			(952)									(952)
Issuance of the Convertible Senior Notes (see	. ,												
Note 4)				5,190									5,190
Dividends declared				,						(38,490)			(38,490)
Stock-based compensation				3,195						(3,195
Tax Reclassification of stockholders equity in				,									,
accordance with generally accepted accounting													
principles				(3,368)				5,250		(1,882)			
Balance at December 31, 2011	43,853	\$	44	\$ 484,244	\$	(3,431)	\$	(43,042)	\$	(6,432)	\$	(342)	\$ 431,041
Net increase in net assets resulting from													
operations		\$		\$	\$	(4,516)	\$	3,168	\$	48,107	\$		\$ 46,759
Issuance of common stock	578		1	3,287									3,288
Issuance of common stock under restricted													
stock plan	505												
Issuance of common stock as stock dividend.	219			2,305									2,305
Retired shares from net issuance	(330)			(4,625)									(4,625)
Public Offering	8,100		8	80,872									80,880
Dividends declared										(47,983)			(47,983)
Stock-based compensation				4,303									4,303
Tax Reclassification of stockholders equity in													
accordance with generally accepted accounting													
principles				(5,878)				2,958		2,920			
Balance at December 31, 2012	52,925	\$	53	\$ 564,508	\$	(7,947)	\$	(36,916)	\$	(3,388)	\$	(342)	\$ 515,968
Buillice at December 51, 2012	52,725	Ψ	00	\$ 501,500	Ψ	(7,517)	Ψ	(50,710)	Ψ	(5,500)	Ψ	(312)	¢ 515,900
Net increase in net assets resulting from		<i>•</i>		<i>.</i>	<i>•</i>		<i>•</i>	11026	<i>•</i>				• • • • • • • • •
operations	0.010	\$	0	\$	\$	11,545	\$	14,836	\$	73,065	\$		\$ 99,446
Issuance of common stock	2,019		2	25,245									25,247
Issuance of common stock under restricted	100												
stock plan	423		1	(1)									0.001
Issuance of common stock as stock dividend	159			2,201									2,201
Retired shares from net issuance	(1,739)		(2)	(27,990)									(27,992)
Public Offering	8,050		8	95,529									95,537
Dividends declared										(66,454)			(66,454)

Stock-based compensation			6,054					6,054
Tax Reclassification of stockholders equity in accordance with generally accepted accounting principles			(8,952)		6,840	2,112		
Balance at December 31, 2013	61,837	\$ 62	\$ 656,594	\$ 3,598	\$ (15,240)	\$ 5,335	\$ (342)	\$ 650,007

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

	2013	December 31, 2012	2011
Cash flows from operating activities:			
Net increase in net assets resulting from operations	\$ 99,446	\$ 46,759	\$ 46,936
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used			
in) operating activities:	(407.550)	(505.000)	(115.0(6)
Purchase of investments	(487,558)	(507,098)	(445,066)
Principal payments received on investments	477,535	245,777	247,325
Proceeds from sale of investments	44,832	25,948	17,733
Net (increase) decrease in unrealized (appreciation) / depreciation on investments	(11,545)	4,516	(4,607)
Net realized gain on investments	(14,836)	(3,048)	(2,741)
Accretion of paid-in-kind principal Accretion of loan discounts	(3,103)	(1,400)	(1,943)
Accretion of loan discount on Convertible Senior Notes	(6,652)	(5,441)	(6,999)
Accretion of loan exit fees	1,083	1,083	767
	(9,251) 1,409	(3,986) 2,301	(94)
Change in deferred loan origination revenue Unearned fees related to unfunded commitments	(3,087)	(1,900)	2,420 615
Amortization of debt fees and issuance costs	4,044	1,560	1,688
Depreciation	4,044	289	348
Stock-based compensation and amortization of restricted stock grants	6,054	4,303	3,195
	0,054	4,505	5,195
Change in operating assets and liabilities: Interest and fees receivable (payable)	672	(3,815)	(1,300)
Prepaid expenses and other assets		,	318
Accounts payable	2,488 54	(988) 279	(563)
Accrued liabilities	1,757	926	2,443
Accrued natifilies	1,757	920	2,443
Net cash provided by (used in) operating activities	103,594	(193,935)	(139,525)
Cash flows from investing activities:			
Purchases of capital equipment	(311)	(87)	(189)
Investment in restricted cash	(6,271)	, í	, í
Other long-term assets			(25)
Net cash used in investing activities	(6,582)	(87)	(214)
Cash flows from financing activities:			
Proceeds from issuance of common stock, net	92,376	79,647	30
Dividends paid	(64,252)	(45,678)	(36,843)
Issuance of Convertible Senior Notes			75,000
Issuance of 2019 Notes Payable		170,365	
Issuance of Asset-Backed Notes		129,300	
Repayments of Asset-Backed Notes	(39,743)		
Borrowings of credit facilities		64,000	92,500
Repayments of credit facilities		(74,228)	(27,313)
Cash paid for debt issuance costs		(10,864)	(3,110)
Fees paid for credit facilities and debentures	(19)		(3,065)
Net cash provided by (used in) financing activities	(11,638)	312,542	97,199
Net increase (decrease) in cash and cash equivalents	85,374	118,520	(42,540)
Cash and cash equivalents at beginning of year	182,994	64,474	107,014
Cash and cash equivalents at end of year	\$ 268,368	\$ 182,994	\$ 64,474

Supplemental disclosures:					
Interest paid		\$	25,245	\$ 18,928	\$ 11,270
Income taxes paid		\$	85	\$ 44	\$ 66
Stock dividend		\$	2,201	\$ 2,305	\$ 1,649
	0	° 11			

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor		incipal mount	Cost ⁽²⁾	V	alue ⁽³⁾
Debt									
Biotechnology Tools									
1-5 Years Maturity									
Labcyte, Inc. ⁽¹¹⁾	Biotechnology Tools	Senior Secured	June 2016	Interest rate PRIME + 6.70% or Floor rate of 9.95%	\$	4,270	\$ 4,323	\$	4,289
Subtotal: 1-5 Years Maturity							4,323		4,289
Subtotal: Biotechnology Tools (0.66%)*						4,323		4,289
Energy Technology									
Under 1 Year Maturity									
American Superconductor	Energy	Senior Secured	December	Interest rate PRIME + 7.25%					
Corporation ⁽³⁾⁽¹¹⁾	Technology	~	2014	or Floor rate of 11.00%	\$	4,615	4,991		4,991
Brightsource Energy, Inc.	Energy	Senior Secured	January	Interest rate Prime $+$ 8.25% or			15.000		1 - 004
	Technology	0 2 0 1	2014	Floor rate of 11.50%	\$	15,000	15,886		15,886
Enphase Energy, Inc. ⁽¹¹⁾	Energy Technology	Senior Secured	June 2014	Interest rate PRIME + 5.75% or Floor rate of 9.00%	\$	1,315	1,358		1,358
	reemology			of 11001 face of 9.00%	Ψ	1,515	1,550		1,550
Subtotal: Under 1 Year Maturity							22,236		22,236
1-5 Years Maturity									
Agrivida, Inc.	Energy Technology	Senior Secured	December 2016	Interest rate PRIME + 6.75% or Floor rate of 10.00%	\$	6,000	5,887		5,770
American Superconductor	Energy	Senior Secured	November	Interest rate PRIME + 7.25%					
Corporation ⁽³⁾⁽¹¹⁾	Technology		2016	or Floor rate of 11.00%	\$	10,000	9,801		9,801
APTwater, Inc	Energy Technology	Senior Secured	April 2017	Interest rate PRIME + 6.75% or Floor rate of 10.00%, PIK Interest 2.75%	¢	18,085	17,874		17 074
BioAmber, Inc. ⁽⁵⁾⁽¹⁰⁾	Energy	Senior Secured	June 2016	Interest rate PRIME + 6.75%	φ	18,085	17,074		17,874
bior moor, me. A bior	Technology	Senior Secured	June 2010	or Floor rate of 10.00%	\$	25,000	25,298		25,798
Enphase Energy, Inc. ⁽¹¹⁾	Energy Technology	Senior Secured	August 2016	Interest rate PRIME + 8.25% or Floor rate of 11.50%	\$	7,400	7,422		7.314
Fluidic, Inc.	Energy Technology	Senior Secured	March 2016	Interest rate PRIME + 8.00% or Floor rate of 11.25%	\$	5,000	4,922		4,922
Fulcrum Bioenergy, Inc.(11)	Energy Technology	Senior Secured	November 2016	Interest rate PRIME + 7.75% or Floor rate of 11.00%		10,000	9,944		9,694
Glori Energy, Inc. ⁽¹¹⁾	Energy Technology	Senior Secured	June 2015	Interest rate PRIME + 6.75% or Floor rate of 10.00%		5,333	5,457		5,414
Polyera Corporation	Energy	Senior Secured	June 2016	Interest rate PRIME + 6.75%	φ	5,555	5,457		5,414
<u>r</u>	Technology			or Floor rate of 10.00%	\$	5,809	5,797		5,686
SCIEnergy, Inc. ⁽⁴⁾	Energy	Senior Secured	September	Interest rate PRIME + 8.75%					
	Technology		2015	or Floor rate of 12.00%	\$	4,448	4,596		4,685
Scifiniti (pka Integrated Photovoltaics,	Energy	Senior Secured	February	Interest rate PRIME + 7.38%	¢	1 462	1 4 4 2		1 420
Inc.) Stion Corporation (4)(6)	Technology	Senior Secured	2015	or Floor rate of 10.63%	\$ \$	1,463 4,571	1,443 4,005		1,429 4,096
Stion Corporation. ⁽⁴⁾⁽⁶⁾		Senior Secured			ф	4,371	4,005		4,090

	Energy Technology		February 2015	Interest rate PRIME + 6.75% or Floor rate of 10.00%			
TAS Energy, Inc.	Energy	Senior Secured	February	Interest rate PRIME + 7.75%			
	Technology		2015	or Floor rate of 11.00%	\$ 15,000	15,277	15,421
	Energy	Senior Secured	February	Interest rate PRIME + 6.25%			
	Technology		2015	or Floor rate of 9.50%	\$ 4,503	4,374	4,338
Total TAS Energy, Inc.						19,651	19,760
TPI Composites, Inc.	Energy	Senior Secured	June 2016	Interest rate PRIME + 8.00%			
	Technology			or Floor rate of 11.25%	\$ 15,000	14,888	14,889
Subtotal: 1-5 Years Maturity						136,985	137,131
Subtotal: Energy Technology (24.52	2%)* ⁽¹³⁾					159,221	159,367
						,	-

F-8

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

Derth R. Commune	Sach Jas Jas et an	Type of	Maturity	Internet Determid Flerer	Principal	C = =4(2)	V-l(3)
Portfolio Company	Sub-Industry	Investment ⁽¹⁾	Date	Interest Rate and Floor	Amount	Cost ⁽²⁾	Value ⁽³⁾
Communications & Networking							
1-5 Years Maturity							
OpenPeak, Inc. ⁽¹¹⁾	Communications & Networking	Senior Secured	July 2015	Interest rate PRIME + 8.75% or Floor rate of 12.00%	\$ 10,029	\$ 10,714	\$ 10,814
Spring Mobile Solutions, Inc.	Communications & Networking	Senior Secured	November 2016	Interest rate PRIME + 8.00% or Floor rate of 11.25%	\$ 20,000	19,682	19,875
Subtotal: 1-5 Years Maturity						30,396	30,690
Subtotal: Communications & Networking (4.72%)*							30,690
Drug Delivery							
1-5 Years Maturity							
AcelRx Pharmaceuticals, Inc. ⁽³⁾⁽¹⁰⁾	Drug Delivery	Senior Secured	October	Interest rate PRIME +			

AcelRx Pharmaceuticals, Inc. ⁽³⁾⁽¹⁰⁾	Drug Delivery	Senior Secured	October 2017	Interest rate PRIME + 3.85% or Floor rate of 9.10%	¢	15,000	14,556	15,006
BIND Therapeutics, Inc. ⁽³⁾	Drug Delivery	Senior Secured	September 2016	Interest rate Prime + 7.00% or Floor rate of 10.25%	\$	4,500	4,407	4,458
Celsion Corporation ⁽³⁾	Drug Delivery	Senior Secured	June 2017	Interest rate Prime + 8.00% or Floor rate of 11.25%	\$		4,897	4,897
Dance Biopharm, Inc.	Drug Delivery	Senior Secured	August 2017	Interest rate PRIME + 7.4% or Floor rate of 10.65%	\$	1,000	974	974
Intelliject, Inc. ⁽¹¹⁾	Drug Delivery	Senior Secured	June 2016	Interest rate PRIME + 5.75% or Floor rate of 11.00%	\$	15,000	15,150	15,450
NuPathe, Inc. ⁽³⁾	Drug Delivery	Senior Secured	May 2016	Interest rate Prime - 3.25% or Floor rate of 9.85%	\$	5,749	5,629	5,744
Revance Therapeutics, Inc.	Drug Delivery	Senior Secured	March 2015	Interest rate PRIME + 6.60% or Floor rate of 9.85%	\$	9,798	10,032	9,943
	Drug Delivery	Senior Secured	March 2015	Interest rate PRIME + 6.60% or Floor rate of 9.85%	\$	980	1,011	994
Total Revance Therapeutics, Inc.				7.05 //	ψ	700	11,043	10,937
Subtotal: 1-5 Years Maturity							56,655	57,466
Subtotal: Drug Delivery (8.84%)*							56,655	57,466
Drug Discovery & Development								

1-5 Years Maturity

ADMA Biologics, Inc. ⁽³⁾	Drug Discovery & Development	Senior Secured	April 2016	Interest rate Prime + 2.75% or Floor rate of 8.50%	\$ 5,000	4,956	4,892
Anacor Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Secured	July 2017	Interst rate PRIME + 6.40% or Floor rate of 11.65%	\$ 30,000	29,083	29,810
Aveo Pharmaceuticals, Inc. ⁽³⁾⁽¹⁰⁾⁽¹¹⁾	Drug Discovery & Development	Senior Secured	September 2015	Interest rate PRIME + 7.15% or Floor rate of 11.90%	\$ 19,396	19,396	19,590
Cell Therapeutics, Inc. ⁽³⁾⁽¹¹⁾	Drug Discovery & Development	Senior Secured	October 2016	Interest rate Prime + 9.00% or Floor rate of 12.25%	\$ 15,000	14,750	15,200
Cempra, Inc. ⁽³⁾⁽¹¹⁾	Drug Discovery & Development	Senior Secured	June 2017	Interest rate PRIME + 6.30% or Floor rate of 9.55%	\$ 15,000	14,795	14,550
Cleveland BioLabs, Inc. ⁽³⁾	Drug Discovery & Development	Senior Secured	January 2017	Interest rate PRIME + 6.20% or Floor rate of 10.45%	\$ 6,000	5,909	5,909
Concert Pharmaceuticals, Inc. ⁽⁴⁾	Drug Discovery & Development	Senior Secured	October 2015	Interest rate PRIME + 3.25% or Floor rate of 8.50%	\$ 15,091	14,933	14,649
Coronado Biosciences, Inc. ⁽³⁾⁽¹¹⁾	Drug Discovery & Development	Senior Secured	March 2016	Interest rate PRIME + 6.00% or Floor rate of 9.25%	\$ 13,654	13,720	13,449
Dicerna Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Secured	January 2015	Interest rate PRIME + 4.40% or Floor rate of 10.15%	\$ 5,026	4,991	4,981
Insmed, Incorporated ⁽¹¹⁾	Drug Discovery & Development	Senior Secured	January 2016	Interest rate PRIME + 4.75% or Floor rate of 9.25%	\$ 20,000	19,708	19,535
Merrimack Pharmaceuticals, Inc. ⁽³⁾	Drug Discovery & Development	Senior Secured	November 2016	Interest rate PRIME + 5.30% or Floor rate of 10.55%	\$ 40,000	40,314	39,455
Neuralstem, Inc. ⁽³⁾	Drug Discovery & Development	Senior Secured	June 2016	Interest rate PRIME + 7.75% or Floor rate of 11.00%	\$ 8,000	7,874	8,035

F-9

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor		ncipal 10unt	Cost ⁽²⁾	Value ⁽³⁾
Paratek Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Secured	N/A	Interest rate Fixed 10.00%	\$	36	\$ 36	\$
	Drug Discovery & Development	Senior Secured	N/A	Interest rate Fixed 10.00%	\$	45	45	
	Drug Discovery & Development	Senior Secured	N/A	N/A	\$	28	28	
Total Paratek Pharmaceuticals, Inc.					\$	109	109	
uniQure B.V. ⁽⁵⁾⁽¹⁰⁾⁽¹¹⁾	Drug Discovery & Development	Senior Secured	October 2016	Interest rate PRIME + 8.60% or Floor rate of 11.85%	\$ 1	0.000	9,695	9,818
Subtotal: 1-5 Years Maturity							200,232	199,872
Subtotal: Drug Discovery & Developme	ent (30.75%)*						200,232	199,872

Electronics & Computer Hardware

1-5 Years Maturity							
Clustrix, Inc.	Electronics & Computer Hardware	Senior Secured	December 2015	Interest rate PRIME + 6.50% or Floor rate of 9.75%	\$ 524	526	526
Identive Group, Inc. ⁽³⁾⁽¹¹⁾	Electronics & Computer Hardware	Senior Secured	November 2015	Interest rate PRIME + 7.75% or Floor rate of 11.00%	\$ 5,938	5,696	5,755
OCZ Technology Group, Inc.	Electronics & Computer Hardware	Senior Secured	April 2016	Interest rate Prime + 8.75% or Floor rate of 12.50%, PIK Interest 3.00%	\$ 1,221	1,221	1,221
Plures Technologies, Inc. ⁽³⁾	Electronics & Computer Hardware	Senior Secured	October 2016	Interest rate Prime + 12.75% or Floor rate of 16.00%, PIK Interest 4.00%	\$ 2,046	1,958	1,458
Subtotal: 1-5 Years Maturity						9,400	8,959

Subtotal: Electronics & Computer Hardware (1.38%)*

Healthcare Services, Other

1-5 Years Maturity							
InstaMed Communications, LLC	Healthcare Services, Other	Senior Secured	December 2016	Interest rate PRIME + 7.25% or Floor rate of 10.50%	\$ 3,000	2,979	2,979
MDEverywhere, Inc.	Healthcare Services, Other	Senior Secured	June 2016	Interest rate LIBOR + 9.50% or Floor rate of 10.75%	\$ 2,000	1,875	1,907

8,959

9,400

Orion Healthcorp, Inc.	Healthcare Services, Other	Senior Secured	June 2017	Interest rate LIBOR + 10.50% or Floor rate of 12.00%, PIK Interest 3.00%	\$	6,591	6,467	6,413
	Healthcare Services, Other	Senior Secured	June 2017	Interest rate LIBOR + 9.50% or Floor rate of 11.00%	\$	9,000	8,838	8,445
	Healthcare Services, Other	Senior Secured	June 2016	Interest rate LIBOR + 8.25% or Floor rate of 9.50%	\$	500	465	461
Total Orion Healthcorp, Inc.					\$	16,091	15,769	15,318
Pacific Child & Family Associates, LLC	Healthcare Services, Other	Senior Secured	January 2015	Interest rate LIBOR + 9.00% or Floor rate of 11.50%	\$	1,946	2,017	1,988
	Healthcare Services, Other	Senior Secured	January 2015	Interest rate LIBOR + 11.00% or Floor rate of 14.00%, PIK interest 3.75%	\$	6,836	6,867	6,833
				517570	Ψ	0,000	0,007	0,000
Total Pacific Child & Family Associates,	LLC				\$	8,782	8,884	8,822
Subtotal: 1-5 Years Maturity							29,508	29,025
Subtotal: Healthcare Services, Other (4	.47%)*						29,508	29,025

F-10

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor		icipal iount	Cost ⁽²⁾	Value ⁽³⁾
Information Services								
1-5 Years Maturity								
Eccentex Corporation ⁽¹¹⁾	Information Services	Senior Secured	May 2015	Interest rate PRIME + 7.00% or Floor rate of 10.25%	\$	657	\$ 658	\$ 185
InXpo, Inc.	Information Services	Senior Secured	April 2016	Interest rate PRIME + 7.50% or Floor rate of 10.75%	\$ 2	2,550	2,489	2,384
Jab Wireless, Inc.	Information Services	Senior Secured	November 2017	Interest rate Libor + 6.75% or Floor rate of 8.00%	\$ 30	0,000	29,822	29,822
	Information Services	Senior Secured	November 2017	Interest rate Prime + 6.75% or Floor rate of 8.00%	\$ 2	2,000	1,996	1,996
Total Jab Wireless, Inc.					\$ 32	2,000	31,818	31,818
Womensforum.com ⁽¹¹⁾	Information Services	Senior Secured	October 2016	Interest rate LIBOR + 7.50% or Floor rate of 10.25%, PIK Interest 2.00%	¢	4,607	4,536	4,127
	Information Services	Senior Secured	October 2016	Interest 2.00% Interest rate LIBOR + 6.50% or Floor rate of 9.25%		6,900	6,793	6,470
	Information Services	Senior Secured		Interest rate LIBOR + 6.50% or Floor rate of 9.00%		1,250	1,227	1,156
Total Womensforum.com					\$ 12	2,757	12,556	11,754
Subtotal: 1-5 Years Maturity							47,521	46,140
Subtotal: Information Services (7.10%)*	\$						47,521	46,140
Internet Consumer & Business Services								
Under 1 Year Maturity								
Gazelle, Inc.	Internet Consumer & Business Services	Senior Secured	October 2014	Interest rate PRIME + 6.50% or Floor rate of 9.75%	\$ 2	2,137	2,115	2,115
Tectura Corporation ⁽⁸⁾	Internet Consumer & Business Services	Senior Secured	May 2014	Interest rate LIBOR + 10.00% or Floor rate of 13.00%	\$ (6,468	6,467	3,566
	Internet Consumer & Business Services	Senior Secured	May 2014	Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%	\$ 10	0,777	10,777	5,943
	Internet Consumer & Business Services	Senior Secured	May 2014	Interest rate LIBOR + 10.00% or Floor rate of 13.00%	\$	563	563	310
	Internet Consumer & Business Services	Senior Secured	May 2014	Interest rate LIBOR + 10.00% or Floor rate of 13.00%	\$:	5,000	5,000	2,757
Total Tectura Corporation					\$ 22	2,807	22,806	12,576
Subtotal: Under 1 Year Maturity							24,921	14,691

1-5 Years Maturity							
Blurb, Inc.	Internet Consumer & Business Services	Senior Secured	December 2015	Interest rate PRIME + 5.25% or Floor rate of 8.50%	\$ 6,351	6,216	6,054
CashStar, Inc.	Internet Consumer & Business Services	Senior Secured	June 2016	Interest rate Prime + 6.25% or Floor rate 10.50%, PIK Interest 1.00%	\$ 4,018	3,944	3,916
Education Dynamics, LLC	Internet Consumer & Business Services	Senior Secured	March 2016	Interest rate Libor + 12.5% or Floor rate 12.50%, PIK Interest 1.5%	\$ 24,685	24,284	23,582
Gazelle, Inc.	Internet Consumer & Business Services	Senior Secured	April 2016	Interest rate Prime + 7.00% or Floor rate of 10.25%, PIK Interest 2.50%	\$ 12,365	12,283	12,128
Just Fabulous, Inc.	Internet Consumer & Business Services	Senior Secured	February 2017	Interest rate PRIME + 8.25% or Floor rate of 11.50%	\$ 5,000	4,842	4,842

F-11

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor		incipal mount	Cost ⁽²⁾	Value ⁽³⁾
NetPlenish ⁽⁸⁾	Internet Consumer & Business Services	Senior Secured	September 2015	Interest rate FIXED 10.00%	\$	383	\$ 375	\$
	& Business Services & Business Services	Senior Secured		Interest rate FIXED 10.00%	\$	97	97	
Total NetPlenish					\$	480	472	
Reply! Inc. ⁽¹¹⁾	Internet Consumer & Business Services	Senior Secured	February 2016	Interest rate PRIME + 7.25% or Floor rate of 10.50%, PIK Interest 2.00%	\$	3,031	3,051	3,034
	Internet Consumer & Business Services	Senior Secured	September 2015	Interest rate Prime + 6.88% or Floor rate of 10.13%, PIK Interest 2.00%	\$	9,169	9,086	9,169
	Internet Consumer & Business Services	Senior Secured	September 2015	Interest rate Prime + 7.25% or Floor rate of 11.00%, PIK Interest 2.00%	\$	2,020	2,044	2,070
Total Reply! Inc.						14,220	14,181	14,273
ShareThis, Inc.	Internet Consumer & Business Services	Senior Secured	June 2016	Interest rate PRIME + 7.50% or Floor rate of 10.75%	\$	14,578	14,160	14,160
VaultLogix, LLC	Internet Consumer & Business Services	Senior Secured	September 2015	Interest rate LIBOR + 7.00% or Floor rate of 8.50%	\$	7,897	7,927	7,525
	Internet Consumer & Business Services	Senior Secured	September 2016	Interest rate LIBOR + 8.50% or Floor rate of 10.00%, PIK interest 2.50%	\$	7,949	7,898	7,397
				210070	Ŷ	,,,,,,,,	1,070	,,057
Total VaultLogix, LLC					\$	15,847	15,826	14,923
WaveMarket, Inc. ⁽¹¹⁾	Internet Consumer & Business Services	Senior Secured	September 2015	Interest rate Prime + 5.75% or Floor rate of 9.50%	\$	10,000	9,940	9,665
Subtotal: 1-5 Years Maturity							106,148	103,545
Subular, 1-5 Tears Maturity							100,140	105,545
Subtotal: Internet Consumer & Busine	ess Services (18.19%)*						131,069	118,236
Media/Content/Info								
Under 1 Year Maturity			_	_				
Zoom Media Group, Inc.	Media/Content/Info	Senior Secured	December 2014	Interest rate PRIME + 5.25% or Floor rate of 8.50%	\$	4,000	3,858	3,858

Subtotal: Under 1 Year Maturity							3,858	3,858
1-5 Years Maturity								
Zoom Media Group, Inc.	Media/Content/Info	Senior Secured	December 2015	Interest rate PRIME + 7.25% and PIK + 3.75% or Floor rate of 10.50%	\$	4,288	4,122	4,071
Subtotal: 1-5 Years Maturity							4,122	4,071
Subtotal: Media/Content/Info (1.22%)*							7,981	7,929
Medical Devices & Equipment								
Under 1 Year Maturity								
Oraya Therapeutics, Inc. ⁽⁹⁾⁽¹¹⁾	Medical Devices & Equipment	Senior Secured	December 2014	Interest rate Fixed 7.00%	\$	500	500	500
Subtotal: Under 1 Year Maturity							500	500
1-5 Years Maturity								
Baxano Surgical, Inc. ⁽³⁾	Medical Devices & Equipment	Senior Secured	March 2017	Interest rate PRIME + 7.75% or Floor rate of 12.5%	\$	7.500	7.222	7,222
Home Dialysis Plus, Inc.	Medical Devices & Equipment	Senior Secured	April 2017	Interest rate PRIME + 6.35% or Floor rate of 9.60%	\$	10,000	9.732	9,732
InspireMD, Inc. ⁽³⁾⁽⁵⁾⁽¹⁰⁾	Medical Devices & Equipment	Senior Secured	February 2017	Interest rate PRIME + 5.00% or Floor rate of 10.50%		10,000	9,732	9,732
Medrobotics Corporation	Medical Devices & Equipment	Senior Secured	March 2016	Interest rate PRIME + 7.85% or Floor rate of 11.10%	\$ \$.,	4,489	4,454
				11.1070	φ	4,501	4,409	4,454

F-12

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor		rincipal mount	Cost ⁽²⁾	Value ⁽³⁾
NetBio, Inc.	Medical Devices & Equipment	Senior Secured	August 2017	Interest rate PRIME + 5.00% or Floor rate of 11.00%	\$	5,000	\$ 4,788	\$ 4,788
NinePoint Medical, Inc.	Medical Devices & Equipment	Senior Secured	January 2016	Interest rate PRIME + 5.85% or Floor rate of 9.10%	\$	5,946	5,911	5,794
Oraya Therapeutics, Inc. ⁽⁹⁾⁽¹¹⁾	Medical Devices & Equipment	Senior Secured	September 2015	Interest rate PRIME + 5.50% or Floor rate of 10.25%		7,064	6,980	7,162
SonaCare Medical, LLC (pka US HIFU, LLC) ⁽¹¹⁾	Medical Devices & Equipment	Senior Secured	April 2016	Interest rate PRIME + 7.75% or Floor rate of 11.00%		5,667	5,754	5,818
United Orthopedic Group, Inc.	Medical Devices & Equipment	Senior Secured	July 2016	Interest rate PRIME + 8.60% or Floor rate of	\$	ĺ		
ViewRay, Inc.	Medical Devices & Equipment	Senior Secured	June 2017	11.85% Interest rate PRIME + 7.00% or Floor rate of 10.25%, PIK Interest 1.50%		25,000 15,000	24,647 14,489	25,166 14,489
Subtotal: 1-5 Years Maturity							93,707	94,320
Subtotal: Medical Devices & Equipment (14.59%)*						94,206	94,819
Semiconductors								
1-5 Years Maturity								
Achronix Semiconductor Corporation	Semiconductors	Senior Secured	January 2015	Interest rate PRIME + 10.60% or Floor rate of 13.85%	\$	1,032	1,023	1,006
SiTime Corporation	Semiconductors	Senior Secured	September 2016	Interest rate PRIME + 6.50% or Floor rate of 9.75%	\$	3,500	3,473	3,473
Subtotal: 1-5 Years Maturity							4,495	4,479
Subtotal: Semiconductors (0.69%)*							4,495	4,479
Software								
Under 1 Year Maturity								
Clickfox, Inc.	Software	Senior Secured	September 2014	Interest rate PRIME + 6.75% or Floor rate of	¢	2 000	1 070	1 070

	becurea	2011	10.00%	\$	2,000	1,979	1,979
Software	Senior Secured	December 2014	Interest rate PRIME + 2.75% or Floor rate of				
			6.00%	\$	200	191	191
Software	Senior Secured	December 2014	Interest rate Prime + 2.25% or Floor rate of 6.50%	\$	3,111	3,071	2,970
		Software Senior Software Secured	SoftwareSenior SecuredDecember 2014SoftwareSeniorDecember	Software Senior December Interest rate PRIME + Secured 2014 2.75% or Floor rate of Software Senior December Interest rate Prime + 2.25%	Software Senior December Interest rate PRIME + Secured 2014 2.75% or Floor rate of Software Senior December Interest rate Prime + 2.25% Software	Software Senior December Interest rate PRIME + 2014 Software Senior 2014 2.75% or Floor rate of Software Senior December Interest rate Prime + 2.25%	SoftwareSenior SecuredDecember 2014Interest rate PRIME + 2.75% or Floor rate of 6.00%2001,979SoftwareSeniorDecemberInterest rate PRIME + 2.75% or Floor rate of 6.00%\$ 2,000191

Subtotal: Under 1 Year Maturity

1-5 Years Maturity							
Clickfox, Inc.	Software	Senior Secured	November 2015	Interest rate PRIME + 8.25% or Floor rate of 11.50%	\$ 5,842	5,530	5,530
Hillcrest Laboratories, Inc.	Software	Senior Secured	July 2015	Interest rate PRIME + 7.50% or Floor rate of 10.75%	\$ 2,660	2,630	2,604
Mobile Posse, Inc.	Software	Senior Secured	December 2016	Interest rate PRIME + 7.50% or Floor rate of 10.75%	\$ 4,000	3,876	3,879
Neos Geosolutions, Inc.	Software	Senior Secured	May 2016	Interest rate Prime + 5.75% or Floor rate of 10.50%	\$ 3,771	3,808	3,705
Sonian, Inc.	Software	Senior Secured	July 2017	Interest rate PRIME + 7.00% or Floor rate of 10.25%	\$ 5,500	5,332	5,332
StartApp, Inc.	Software	Senior Secured	March 2017	Interest rate PRIME + 7.75% or Floor rate of 11.00%	\$ 2,500	2,507	2,498
Touchcommerce, Inc.	Software	Senior Secured	June 2017	Interest rate Prime + 6.00% or Floor rate of 10.25%	\$ 5,000	4,688	4,767
Subtotal: 1-5 Years Maturity						28,372	28,315

Subtotal: Software (5.15%)*

33,613 33,455

F-13

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

Specialty Pharmaceuticals 1-5 Years Maturity Rockwell Medical, Inc. Specialty Pharmaceuticals Senior Secured March 2017 Interest rate PRIME + 9.25% or Floor rate of 12.50% \$ 20,000 \$ 20,055 \$ 20,0 Subtotal: 1-5 Years Maturity 20,055 20,055 \$ 20,055 \$ 20,055 \$ 20,055	Denteska Comment	Type of)	Maturity	Interest Rate and Floor		rincipal	Cost ⁽²⁾	Vala	(3)
1-5 Years Maturity Rockwell Medical, Inc. Specialty Pharmaceuticals Senior Secured March 2017 9.25% or Floor rate of 12.50% \$ 20,000 \$ 20,055 \$ 20,055 Subtotal: 1-5 Years Maturity 20,055 20,055 20,055 Subtotal: Specialty Pharmaceuticals (3.09%)* 20,055 20,055 20,055	Portfolio Company	ry investmen	,	Date	Interest Kate and Floor	A	mount	Cost	valu	16(3)
Rockwell Medical, Inc. Specialty Pharmaceuticals Senior Secured 2017 March 2017 Interest rate PRIME + 9.25% or Floor rate of 12.50% \$ 20,000 \$ 20,055 \$ 20,055 Subtotal: 1-5 Years Maturity 20,055 20,055 20,055 20,055 20,055 20,055 Subtotal: Specialty Pharmaceuticals (3.09%)* 20,055 20,055 20,055 20,055										
Pharmaceuticals 2017 9.25% or Floor rate of 12.50% \$ 20,000 \$ 20,055 <th< td=""><td>•</td><td>Conion Coop</td><td>d</td><td>Monoh</td><td>Interest rate DDIME</td><td></td><td></td><td></td><td></td><td></td></th<>	•	Conion Coop	d	Monoh	Interest rate DDIME					
12.50% \$ 20,000 \$ 20,055 \$ 20,055 Subtotal: 1-5 Years Maturity 20,055 20,055 20,055 Subtotal: Specialty Pharmaceuticals (3.09%)* 20,055 20,055 20,055 Surgical Devices 20,055 20,055 20,055	Kockwen Meulcal, Inc.		a							
Subtotal: 1-5 Years Maturity 20,055 20,05 Subtotal: Specialty Pharmaceuticals (3.09%)* 20,055 20,05 Surgical Devices 20,055 20,055		118		2017		¢	20.000	¢ 20.055	\$ 20	055
Subtotal: Specialty Pharmaceuticals (3.09%)* 20,055 20,0 Surgical Devices					12.50%	\$	20,000	\$ 20,055	\$ 20	,055
Subtotal: Specialty Pharmaceuticals (3.09%)* 20,055 20,0 Surgical Devices										
Surgical Devices	Subtotal: 1-5 Years Maturity							20,055	20	,055
Surgical Devices										
0	Subtotal: Specialty Pharmaceuticals (3.09%							20,055	20	,055
0	• • • • •									
1-5 Years Maturity	0									
•										
e	Transmedics, Inc. ⁽¹¹⁾	ces Senior Secu	d			\$	7,250	7,207	7	,207
2015 12.95%				2015	12.95%					
Subtotal: 1-5 Years Maturity 7,207 7,207 7,207	Subtotal: 1-5 Years Maturity							7.207	7	,207
Subtatal Summing Devices (1.1107)* 7.07 7.7	Subtatal Surgical Deviage (1 1107)*							7 207	7	207
Subtotal: Surgical Devices (1.11%)* 7,207 7,2	Subtotal: Surgical Devices (1.11%)*							7,207	/	,207
Total Debt (126.46%)* 835,882 821,9	Total Debt (126.46%)*							835,882	821	,988

F-14

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Equity						
Biotechnology Tools						
NuGEN Technologies, Inc.	Biotechnology Tools	Equity	Preferred Series C	189,394	\$ 500	\$ 687
Subtotal: Biotechnology Tools (0.11	1%)*				500	687
Communications & Networking						
GlowPoint, Inc. ⁽³⁾	Communications &					
	Communications &					
	Networking	Equity	Common Stock	114,192	102	157
Peerless Network, Inc.	Communications &					
	Networking	Equity	Preferred Series A	1,000,000	1,000	3,621
Stoke, Inc.	Communications &					
	Networking	Equity	Preferred Series E	152,905	500	224
Subtotal: Communications & Netw	orking (0.62%)*				1.602	4.002
	or ming (0102 /0)				1,002	1,002
Consumer & Business Products						
Caivis Acquisition Corporation	Consumer &					
	Business Products	Equity	Common Stock	295,861	819	598
IPA Holdings, LLC	Consumer &					
-	Business Products	Equity	LLC Interest	500,000	500	676
Market Force Information, Inc.	Consumer &					
	Business Products	Equity	Preferred Series B	187,970	500	285
Subtotal: Consumer & Business Pr	roducts (0.24%)*				1,819	1,559
Diagnostic	D' d'	P 14	G 6: 1	027.000	750	750
Singulex, Inc.	Diagnostic	Equity	Common Stock	937,998	750	750
Subtotal: Diagnostic (0.12%)*					750	750
Drug Delivery						
AcelRx Pharmaceuticals, Inc. ⁽³⁾⁽¹⁰⁾	Drug Delivery	Equity	Common Stock	89,243	178	1,009
Merrion Pharmaceuticals,			~ ~ .			
$Plc^{(3)(5)(10)}$	Drug Delivery	Equity	Common Stock	20,000	9	
NuPathe, Inc. ⁽³⁾	Drug Delivery	Equity	Common Stock	50,000	146	164
Transcept Pharmaceuticals, Inc. ⁽³⁾	Drug Delivery	Equity	Common Stock	41,570	500	140
Subtotal: Drug Delivery (0.20%)*					833	1,313
Drug Discovery & Development		P				
Acceleron Pharma, Inc. ⁽³⁾		Equity	Common Stock	256,410	1,505	9,286

	Drug Discovery &					
	Development					
Aveo Pharmaceuticals, Inc. ⁽³⁾⁽¹⁰⁾	Drug Discovery &					
	Development	Equity	Common Stock	167,864	842	307
Dicerna Pharmaceuticals, Inc. ⁽¹²⁾	Drug Discovery &	Equity	Common Stock	107,004	042	507
Dicerna i narmaceuticais, me.	<i>c</i> ,	E i		20 107	502	229
	Development	Equity	Preferred Series B	20,107	503	228
	Drug Discovery &					
	Development	Equity	Preferred Series C	142,858	1,000	1,055
Total Dicerna Pharmaceuticals, Inc.				162,965	1,503	1,283
Inotek Pharmaceuticals Corporation	Drug Discovery &			102,905	1,000	1,205
motek Filarmaceuticals Corporation	0	E it	Common Stools	15 224	1 500	
	Development	Equity	Common Stock	15,334	1,500	
Merrimack Pharmaceuticals, Inc. ⁽³⁾	Drug Discovery &					
	Development	Equity	Common Stock	546,448	2,000	2,912
Paratek Pharmaceuticals, Inc.	Drug Discovery &					
	Development	Equity	Common Stock	85,450	5	
	Drug Discovery &	1 2				
	Development	Equity	Preferred Series H	244,158	1,000	
	Development	Equity	Therefield belies II	244,150	1,000	
Total Paratek Pharmaceuticals, Inc.				329,608	1,005	
	(0.100))*				0.055	10 700
Subtotal: Drug Discovery & Develo	opment (2.12%)*				8,355	13,788

F-15

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

			~ .	~	~	
Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Information Services		P 14	D (10 ' C	0(2.159	¢ 250	¢
Buzznet, Inc.	Information Services	Equity	Preferred Series C	263,158	\$ 250	\$
Good Technologies, Inc. (pka Visto			G 0. 1	500.000	(02	
Corporation)	Information Services	Equity	Common Stock	500,000	603	
Subtotal: Information Services (0.00%)*				853	
Internet Consumer & Business Service	S					
Blurb, Inc.	Internet Consumer &					
	Business Services	Equity	Preferred Series B	220,653	175	444
Philotic, Inc.	Internet Consumer &	1 5		.,		
,	Business Services	Equity	Common Stock	8,121	92	
Progress Financial	Internet Consumer &	1 5		- /		
0	Business Services	Equity	Preferred Series G	218,351	250	280
Trulia, Inc. ⁽³⁾	Internet Consumer &	1 2	Common Stock	- /		
	Business Services	-1		29,340	141	1,035
				,		<i>,</i>
Subtotal: Internet Consumer & Busine	ess Services (0.27%)*				658	1,759
Media/Content/Info						
Everyday Health, Inc. (pka Waterfront						
Media, Inc.)	Media/Content/Info	Equity	Preferred Series D	145,590	1,000	425
Subtotal: Media/Content/Info (0.07%)	*				1,000	425
Medical Devices & Equipment						
Gelesis, Inc. ⁽⁶⁾	Medical Devices &					
Gelesis, me.	Equipment	Equity	LLC Interest	2,024,092	925	466
Medrobotics Corporation	Medical Devices &	Equity	ELC interest	2,024,072	123	400
Mediobolies corporation	Equipment	Equity	Preferred Series E	136,798	250	269
Novasys Medical, Inc.	Medical Devices &	Equity	Trefeffed Series E	150,790	250	207
rto vasys medical, me.	Equipment	Equity	Preferred Series D-1	4,118,444	1,000	
Optiscan Biomedical, Corp. ⁽⁶⁾	Medical Devices &	Equity	Treferred Series D T	1,110,111	1,000	
opuoran Bronneurean, corp.	Equipment	Equity	Preferred Series B	6,185,567	3,000	411
	Medical Devices &	Equity	Treferred Serres B	0,100,007	2,000	
	Equipment	Equity	Preferred Series C	1,927,309	655	135
	Medical Devices &	Equity	Trefferred Serres C	1,727,007	000	100
	Equipment	Equity	Preferred Series D	41,352,489	3,945	4,006
Total Optiscan Biomedical, Corp.				49,465,365	7,600	4,552
Subtatal, Madical Davison & Fasting	nt (0.81%)*				9,775	5,287
Subtotal: Medical Devices & Equipment	nt (0.01 %)*				9,113	3,287
Software						
Atrenta, Inc.	Software	Equity	Preferred Series C	1,196,845	986	1,607

Table of Contents

	Software	Equity	Preferred Series D	635,513	508	1,088
Total Atrenta, Inc.				1,832,358	1,494	2,695
Box, Inc.	Software	Equity	Preferred Series C	390,625	500	7,031
	Software	Equity	Preferred Series D	158,133	500	2,846
	Software	Equity	Preferred Series D-1	124,511	1,000	2,241
	Software	Equity	Preferred Series D-2	220,751	2,001	3,974
	Software	Equity	Preferred Series E	38,183	500	687
Total Box, Inc.				932,203	4,501	16,779
CapLinked, Inc.	Software	Equity	Preferred Series A-3	53,614	51	94
ForeScout Technologies, Inc.	Software	Equity	Preferred Series D	319,099	398	849
HighRoads, Inc.	Software	Equity	Preferred Series B	190,170	307	337

Subtotal: Software (3.19%)*

6,751 20,754

F-16

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Specialty Pharmaceuticals						
QuatRx Pharmaceuticals Company	Specialty					
	Pharmaceuticals	Equity	Preferred Series E	241,829	\$ 750	\$
	Specialty	-	Preferred Series			
	Pharmaceuticals	Equity	E-1	26,955		
	Specialty Pharmaceuticals	Fauity	Preferred Series G	4,667,636		
	Pharmaceuticais	Equity	Pleiened Series G	4,007,030		
Total QuatRx Pharmaceuticals Company				4,936,420	750	
Subtotal: Specialty Pharmaceuticals (0.00	%)*				750	
Surgical Devices						
Gynesonics, Inc.	Surgical Devices	Equity	Preferred Series B	219,298	250	73
	Surgical Devices	Equity	Preferred Series C	656,538	282	123
	Surgical Devices	Equity	Preferred Series D	1,621,553	580	749
Total Gynesonics, Inc.				2,497,389	1,112	945
Transmedics, Inc.	Surgical Devices	Equity	Preferred Series B	88,961	1,100	303
	Surgical Devices	Equity	Preferred Series C	119,999	300	212
	Surgical Devices	Equity	Preferred Series D	260,000	650	886
Total Transmedics, Inc.				468,960	2,050	1,401
Subtotal: Surgical Devices (0.36%)*					3,162	2,346
Total Equity (8.10%)*					36,808	52,670
Warrant						
Biotechnology Tools						
Labcyte, Inc.	Biotechnology Tools		Preferred Series C	1,127,624	323	65
NuGEN Technologies, Inc.	Biotechnology Tools	Warrant	Preferred Series B	234,659	78	234
Subtotal: Biotechnology Tools (0.05%)*					401	299
Energy Technology						
Agrivida, Inc.	Energy Technology	Warrant	Preferred Series C	77,447	120	243
Alphabet Energy, Inc.	Energy Technology	Warrant	Preferred Series A	86,329	82	176
American Superconductor Corporation ⁽³⁾	Energy Technology	Warrant	Common Stock	512,820	391	175
Brightsource Energy, Inc.	Energy Technology	Warrant	Preferred Series 1	175,000	780	214
Calera, Inc.	Energy Technology	Warrant	Preferred Series C	44,529	513	
EcoMotors, Inc.	Energy Technology	Warrant	Preferred Series B	437,500	308	475
Fluidic, Inc.	Energy Technology	Warrant	Preferred Series C	59,665	102	138
Fulcrum Bioenergy, Inc.	Energy Technology	Warrant		280,897	275	210

			Preferred Series C-1			
Glori Energy, Inc.	Energy Technology	Warrant	Preferred Series C	145,932	165	50
GreatPoint Energy, Inc.	Energy Technology	Warrant	Preferred Series			
			D-1	393,212	548	
Polyera Corporation	Energy Technology	Warrant	Preferred Series C	161,575	69	44
Propel Fuels	Energy Technology	Warrant	Preferred Series C	3,200,000	211	233
SCIEnergy, Inc.	Energy Technology	Warrant	Preferred Series D	1,061,623	360	2
Scifiniti (pka Integrated Photovoltaics, Inc.)	Energy Technology	Warrant	Preferred Series B	390,000	82	68
Solexel, Inc.	Energy Technology	Warrant	Preferred Series C	1,171,625	1,162	278
Stion Corporation ⁽⁶⁾	Energy Technology	Warrant	Preferred Series			
			Seed	2,154	1,378	1,627
TAS Energy, Inc.	Energy Technology	Warrant	Preferred Series F	428,571	299	756
TPI Composites, Inc.	Energy Technology	Warrant	Preferred Series B	120	172	376
Trilliant, Inc.	Energy Technology	Warrant	Preferred Series A	320,000	162	34
Subtotal: Energy Technology (0.78%)*(13)					7,179	5,099

F-17

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Communications & Networking						
Intelepeer, Inc.	Communications					
	&	N 7		117.050	¢ 100	¢ 110
OpenPeak, Inc.	Networking Communications	Warrant	Preferred Series C	117,958	\$ 102	\$ 112
OpenPeak, Inc.	&					
	Networking	Warrant	Preferred Series 2	108,982	149	
PeerApp, Inc.	Communications			100,902	1.0	
11/	&					
	Networking	Warrant	Preferred Series B	298,779	61	41
Peerless Network, Inc.	Communications					
	&					
	Networking	Warrant	Preferred Series A	135,000	95	368
Ping Identity Corporation	Communications					
	& Networking	Warrant	Preferred Series B	1,136,277	52	98
Spring Mobile Solutions, Inc.	Communications	warrant	Pleiened Series D	1,130,277	52	98
Spring Woone Solutions, me.	&					
	Networking	Warrant	Preferred Series D	2,834,375	417	661
Stoke, Inc.	Communications			, ,		
	&					
	Networking	Warrant	Preferred Series C	158,536	53	5
	Communications					
	&	N 7		70 707	(5	2
	Networking	Warrant	Preferred Series D	72,727	65	2
Total Stake Inc				221 262	118	7
Total Stoke, Inc.				231,263	110	7
Subtotal: Communications & Netwo	orking (0.20%)*				994	1,287
Subtotal. Communications & retwo	(0.20 //)				777	1,207
Consumer & Business Products Intelligent Beauty, Inc.	Consumer &					
intelligent beauty, inc.	Business Products	Warrant	Preferred Series B	190,234	230	1,027
IPA Holdings, LLC	Consumer &	Wallan	Therefield Series B	170,254	250	1,027
	Business Products	Warrant	Common Stock	650,000	275	408
Market Force Information, Inc.	Consumer &					
	Business Products	Warrant	Preferred Series A	99,286	24	1
Subtotal: Consumer & Business Pro	ducts (0.22%)*				529	1,436
Diagnostic						
Navidea Biopharmaceuticals, Inc. (pka	1					
Neoprode) ⁽³⁾	Diagnostic	Warrant	Common Stock	333,333	244	152
• ′	c			,		
Subtotal: Diagnostic (0.02%)*					244	152
Sustouri Diagnostic (002 /0)					217	152

Drug Delivery						
AcelRx Pharmaceuticals, Inc. ⁽³⁾⁽¹⁰⁾	Drug Delivery	Warrant	Common Stock	176,730	786	961
Alexza Pharmaceuticals, Inc.(3)	Drug Delivery	Warrant	Common Stock	37,639	645	1
BIND Therapeutics, Inc. ⁽³⁾	Drug Delivery	Warrant	Common Stock	71,359	367	294
Celsion Corporation ⁽³⁾	Drug Delivery	Warrant	Common Stock	97,493	227	249
Dance Biopharm, Inc.	Drug Delivery	Warrant	Preferred Series A	97,701	74	154
Intelliject, Inc.	Drug Delivery	Warrant	Preferred Series B	82,500	594	1,115
NuPathe, Inc. ⁽³⁾	Drug Delivery	Warrant	Common Stock	106,631	139	136
Revance Therapeutics, Inc. ⁽¹²⁾		Warrant	Preferred Series			
	Drug Delivery		E-5	802,675	557	330
Transcept Pharmaceuticals, Inc. ⁽³⁾	Drug Delivery	Warrant	Common Stock	61,452	87	3

Subtotal: Drug Delivery (0.50%)*

3,476 3,243

Drug Discovery & Development						
Acceleron Pharma, Inc. ⁽³⁾	Drug Discovery					
	&					
	Development	Warrant	Common Stock	11,611	39	294
ADMA Biologics, Inc. ⁽³⁾	Drug Discovery					
	&					
	Development	Warrant	Common Stock	31,750	129	73
Anthera Pharmaceuticals, Inc. ⁽³⁾	Drug Discovery					
	&					
	Development	Warrant	Common Stock	40,178	984	9
Cell Therapeutics, Inc. ⁽³⁾	Drug Discovery					
	&					
	Development	Warrant	Common Stock	679,040	405	601
Cempra, Inc. ⁽³⁾	Drug Discovery					
	&					
	Development	Warrant	Common Stock	138,797	458	728
	Development	vv arrant	Common Stock	150,757	150	720

F-18

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Chroma Therapeutics, Ltd. ⁽⁵⁾⁽¹⁰⁾	Drug Discovery & Development	Warrant	Preferred Series D	325,261	\$ 490	\$ 500
Cleveland BioLabs, Inc ⁽³⁾	Drug Discovery &	warrant	Therefied Series D	525,201	φ +70	φ 500
cievenane Brozaos, me	Development	Warrant	Common Stock	156,250	105	66
Concert Pharmaceuticals, Inc. ⁽¹²⁾	Drug Discovery &					
	Development	Warrant	Preferred Series C	400,000	367	577
Coronado Biosciences, Inc. ⁽³⁾	Drug Discovery &	XX 7	G 0. 1	72.000	1.42	41
Dicerna Pharmaceuticals, Inc. ⁽¹²⁾	Development Drug Discovery &	Warrant	Common Stock	73,009	142	41
Dicema Pharmaceuticais, Inc.	Development	Warrant	Common Stock	200	28	
	Drug Discovery &	Warrant	Common Stock	200	20	
	Development	Warrant	Preferred Series A	21,000	237	38
	Drug Discovery &					
	Development	Warrant	Preferred Series B	26,400	310	48
Total Dicerna Pharmaceuticals, Inc.				47,600	575	86
Horizon Pharma, Inc. ⁽³⁾	Drug Discovery &					
	Development	Warrant	Common Stock	22,408	231	5
Merrimack Pharmaceuticals, Inc. ⁽³⁾	Drug Discovery & Development	Warrant	Common Stock	202 142	155	488
Neuralstem, Inc. ⁽³⁾	Drug Discovery &	warrant	Common Stock	302,143	155	488
iventaisteni, ne.	Development	Warrant	Common Stock	648,798	295	1,045
Portola Pharmaceuticals, Inc. ⁽³⁾	Drug Discovery &	Wullant	Common Stock	010,790	275	1,010
	Development	Warrant	Common Stock	68,702	153	683
uniQure B.V. ⁽⁵⁾⁽¹⁰⁾⁽¹²⁾	Drug Discovery &					
	Development	Warrant	Preferred Series A	185,873	218	313
Subtotal: Drug Discovery & Developme Electronics & Computer Hardware	ent (0.85%)*				4,746	5,509
Clustrix, Inc.	Electronics &					
clusurx, ne.	Computer Hardware	Warrant	Common Stock	50,000	12	16
Identive Group, Inc. ⁽³⁾	Electronics &					
	Computer Hardware	Warrant	Common Stock	992,084	247	136
Plures Technologies, Inc. ⁽³⁾	Electronics &					
	Computer Hardware	Warrant	Preferred Series A	552,467	124	100
Subtotal: Electronics & Computer Har	dware (0 04%)*				383	252
Subtoun. Electromes & Computer Har	uware (0.04 /0)				505	252
Healthcare Services, Other						
MDEverywhere, Inc.	Healthcare Services,					
	Other	Warrant	Common Stock	129	94	55
Subtotal: Healthcare Services, Other (0	0.01%)*				94	55
						50

Information Services

Buzznet, Inc.	Information Services	Warrant	Preferred Series B	19,962	9	
Cha Cha Search, Inc.	Information Services	Warrant	Preferred Series G	48,232	57	10
InXpo, Inc.	Information Services	Warrant	Preferred Series C	648,400	98	45
-			Preferred Series			
	Information Services	Warrant	C-1	582,015	49	40
Total InXpo, Inc.				1,230,415	147	85
Jab Wireless, Inc.	Information Services	Warrant	Preferred Series A	266,567	265	330
RichRelevance, Inc.	Information Services	Warrant	Preferred Series E	112,612	98	
Subtotal: Information Services (0.07%)*					576	425

Internet Consumer & Business Services						
Blurb, Inc.	Internet Consumer &					
	Business Services	Warrant	Preferred Series B	218,684	299	169
	Internet Consumer &					
	Business Services	Warrant	Preferred Series C	234,280	636	248
Total Blurb, Inc.				452.964	935	417
Total Diulo, Inc.				452,904	733	+1/

F-19

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
CashStar, Inc.	Internet Consumer					
	&		Preferred Series			
	Business Services	Warrant	C-2	454,545	\$ 102	\$ 47
Gazelle, Inc.	Internet Consumer					
	&					
	Business Services	Warrant	Preferred Series D	151,827	165	62
Invoke Solutions, Inc.	Internet Consumer					
	&		~ ~ .			
	Business Services	Warrant	Common Stock	53,084	39	
Just Fabulous, Inc.	Internet Consumer					
	& During a Samiana	W/	Durfrand Cruiter D	127 456	590	1.057
Deiem Education Community	Business Services	Warrant	Preferred Series B	137,456	589	1,057
Prism Education Group, Inc.	Internet Consumer &					
	& Business Services	Warrant	Preferred Series B	200,000	43	
Progress Financial	Internet Consumer	w arrain	Ficience Scries B	200,000	43	
Flogress Financiai	&					
	& Business Services	Warrant	Preferred Series G	174,562	78	76
Reply! Inc.	Internet Consumer	warrant	Trefeffed Series G	174,502	70	70
Reply: Inc.	&					
	Business Services	Warrant	Preferred Series B	137,225	320	93
ShareThis, Inc.	Internet Consumer	, and the second s	Therefield Berles B	137,223	520	15
	&					
	Business Services	Warrant	Preferred Series C	493,502	546	241
Tectura Corporation	Internet Consumer)		
	&		Preferred Series			
	Business Services	Warrant	B-1	253,378	51	
WaveMarket, Inc.	Internet Consumer					
	&		Preferred Series			
	Business Services	Warrant	B-1	1,083,779	105	85
Subtotal: Internet Consumer & Busin	ness Services (0.32%)*				2,973	2,078
					_,,	_,
Media/Content/Info						
Everyday Health, Inc. (pka Waterfront						
Media, Inc.)	Media/Content/Info	Warrant	Preferred Series C	110,018	60	50
Glam Media, Inc.	Media/Content/Info	Warrant	Preferred Series D	407,457	482	
Zoom Media Group, Inc.	Media/Content/Info	Warrant	Preferred Series A	1,204	348	275
Subtotal: Media/Content/Info (0.05%)*				890	325
Madial Daviers & Fruitante (
Medical Devices & Equipment						
Baxano Surgical, Inc. ⁽³⁾	Medical Devices					
	& Equipment	Warrant	Common Stock	882,353	439	344
Gelesis, Inc. ⁽⁶⁾	1 1	Warrant	LLC Interest	263,688	78	7
	Medical Devices			200,000	/0	,

	& Equipment					
Home Dialysis Plus, Inc.	Medical Devices					
	& Equipment	Warrant	Preferred Series A	300,000	245	297
InspireMD, Inc. ⁽³⁾⁽⁵⁾⁽¹⁰⁾	Medical Devices					
	inculcul Devices					
	& Equipment	Warrant	Common Stock	168,351	242	167
Medrobotics Corporation	Medical Devices	warrant	Common Stock	100,551	272	107
	Medical Devices					
	& Equipment	Warrant	Preferred Series D	424,008	343	184
	Medical Devices					
	& Equipment	Warrant	Preferred Series E	34,199	27	23
Total Medrobotics Corporation				458,207	370	207
MELA Sciences, Inc. ⁽³⁾	Medical Devices					
	& Equipment	Warrant	Common Stock	693,202	401	94
NetBio, Inc.	Medical Devices			,		
	inculcul Devices					
	& Equipment	Warrant	Common Stock	2,568	408	398
NinePoint Medical, Inc.		vv arrain	Common Stock	2,308	408	390
T (mer omt Wearear, me.	Medical Devices					
			Preferred Series			
	& Equipment	Warrant	A-1	587,840	170	288
Novasys Medical, Inc.	Medical Devices					
	& Equipment	Warrant	Common Stock	109,449	2	
	Medical Devices &					
	Equipment	Warrant	Preferred Series D	526,840	125	
	Medical Devices & Equipment	Warrant	Preferred Series D-1	53,607	6	
	Equipment		D-1	55,007	0	
Tetal Manager Madical Ter				(00.00(122	
Total Novasys Medical, Inc.				689,896	133	

F-20

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Optiscan Biomedical, Corp. ⁽⁶⁾	Medical Devices					
	&					
	Equipment	Warrant	Preferred Series D	10,535,275	\$ 1,252	\$ 232
Oraya Therapeutics, Inc.	Medical Devices					
	&	117	G 0. 1	05 400		22
	Equipment	Warrant	Common Stock	95,498	66	23
	Medical Devices &					
	æ Equipment	Warrant	Preferred Series C	716,948	677	134
	Equipment	warrant	Ficicited Series C	/10,946	077	134
				010 446	7.40	1.57
Total Oraya Therapeutics, Inc.				812,446	743	157
SonaCare Medical, LLC (pka US HIFU,	Medical Devices					
LLC)	&	117	Preferred Series A	400 704	188	201
United Orthopedic Group, Inc.	Equipment Medical Devices	Warrant	Preferred Series A	409,704	188	201
United Orthopedic Group, Inc.	&					
	æ Equipment	Warrant	Preferred Series A	423,076	608	785
ViewRay, Inc.	Medical Devices	warrant	Therefied Series A	425,070	008	785
viewkay, me.	&					
	Equipment	Warrant	Preferred Series C	312,500	333	331
	Equipment	Wulldit	Therefield Berles C	512,500	555	551
	() - 1 07 *				5 (10	2,500
Subtotal: Medical Devices & Equipment	t (0.54%)*				5,610	3,508
Semiconductors						
Achronix Semiconductor Corporation	Semiconductors	Warrant	Preferred Series C	360,000	160	194
SiTime Corporation	Semiconductors	Warrant	Preferred Series G	195,683	24	12
Subtotal: Semiconductors (0.03%)*					184	206
Software						
Atrenta, Inc.	Software	Warrant	Preferred Series D	392,670	121	330
Box, Inc.	Software	Warrant	Preferred Series B	271,070	72	4,701
	Software	Warrant	Preferred Series C	199,219	117	3,331
			Preferred Series			
	Software	Warrant	D-1	62,255	194	625
Total Box, Inc.				532,544	383	8,657
Braxton Technologies, LLC	Software	Warrant	Preferred Series A	168,750	187	0,057
Central Desktop, Inc.	Software	Warrant	Preferred Series B	522,769	107	187
Clickfox, Inc.	Software	Warrant	Preferred Series B	1,038,563	330	495
	Software	Warrant	Preferred Series C	592,019	730	363
						200
Total Clickfox, Inc.				1,630,582	1,060	858
Daegis Inc. (pka Unify Corporation) ⁽³⁾	Software	Warrant	Common Stock	718,860	1,000	83
ForeScout Technologies, Inc.	Software	Warrant	Preferred Series E	80,587	41	82
Hillcrest Laboratories, Inc.	Software	Warrant	Preferred Series E	1,865,650	55	139
Mobile Posse, Inc.	Software	Warrant	Preferred Series C	396,430	130	129
	Solution		Field belies C	570,450	150	127

Naca Cassalutions. Inc.	Software	Warrant	Preferred Series 3	221 150	22	
Neos Geosolutions, Inc.				221,150		105
Sonian, Inc.	Software	Warrant	Preferred Series C	185,949	106	105
SugarSync, Inc.			Preferred Series			
	Software	Warrant	CC	332,726	78	48
			Preferred Series			
	Software	Warrant	DD	107,526	34	16
Total Sugarsync, Inc.				440,252	112	64
Touchcommerce, Inc.	Software	Warrant	Preferred Series E	992,595	251	248
White Sky, Inc.			Preferred Series			
	Software	Warrant	B-2	124,295	54	4
WildTangent, Inc.	Software	Warrant	Preferred Series 3	100,000	238	123
Subtotal: Software (1.69%)*					4,301	11,009
					1,001	11,009
Specialty Pharmaceuticals						
QuatRx Pharmaceuticals Company	Specialty					
	Pharmaceuticals	Warrant	Preferred Series E	155,324	307	
	1 narmaceuticais	vv arrant	I ICICIICU SCIICS E	155,524	307	
California I. Caracitalian Dia anno a cardina la (A	0007 *				207	
Subtotal: Specialty Pharmaceuticals (0.	00%)*				307	

F-21

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares	Cost ⁽²⁾	Value ⁽³⁾
Surgical Devices						
Gynesonics, Inc.	Surgical Devices	Warrant	Preferred Series C	180,480	\$ 74	\$ 27
	Surgical Devices	Warrant	Preferred Series D	1,575,965	320	383
Total Gynesonics, Inc.				1,756,445	394	410
Transmedics, Inc.	Surgical Devices	Warrant	Preferred Series B	40,436	225	9
	Surgical Devices	Warrant	Preferred Series D	175,000	100	335
Total Transmedics, Inc.				215,436	325	344
Subtotal: Surgical Devices (0.12%)*					719	754
Total Warrants (5.48%)*					33,606	35,637
Total Investments (140.04%)*					\$ 906,297	\$ 910,295

- * Value as a percent of net assets
- (1) Preferred and common stock, warrants, and equity interests are generally non-income producing.
- (2) Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled \$48.8 million, \$44.5 million and \$4.3 million respectively. The tax cost of investments is \$906.2 million
- (3) Except for warrants in twenty-five publicly traded companies and common stock in nine publicly traded companies, all investments are restricted at December 31, 2013 and were valued at fair value as determined in good faith by the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
- (4) Debt investments of this portfolio company have been pledged as collateral under the Wells Facility.
- (5) Non-U.S. company or the company s principal place of business is outside the United States.
- (6) Affiliate investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 5% but not more than 25% of the voting securities of the company.
- (7) Control investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owners at least 25% but not more than 50% of the voting securities of the company
- (8) Debt is on non-accrual status at December 31, 2013, and is therefore considered non-income producing.
- (9) Convertible Senior Debt
- (10) Indicates assets that the Company deems not qualifying assets under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company s total assets at the time of acquisition of any additional non-qualifying assets.
- (11) Denotes that all or a portion of the loan secures the notes offered in the Debt Securitization (as defined in Note 4).
- (12) Subsequent to December 31, 2013, this company completed an initial public offering. Note that the December 31, 2013 fair value does not reflect any potential impact of the conversion of our preferred shares to common shares which may include reverse split associated with the offering.
- (13) In our quarterly and annual reports filed with the commission prior to this Annual Report on Form 10-K, we referred to this industry sector as Clean Tech.

F-22

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2012

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾
Debt					
Anthera Pharmaceuticals Inc. ⁽³⁾	Drug	Senior Debt ⁽¹¹⁾			
	Discovery	Matures December 2014			
	&	Interest rate Prime + 7.30% or			
	Development	Floor rate of 10.55%	\$ 20,532	\$ 20,745	\$ 21,007
Aveo Pharmaceuticals, Inc. ⁽³⁾	Drug	Senior Debt ⁽¹¹⁾			
	Discovery	Matures September 2015			
	&	Interest rate Prime + 7.15% or			
	Development	Floor rate of 11.90%	\$ 26,500	26,500	27,030
Cempra, Inc. ⁽³⁾	Drug	Senior Debt ⁽¹¹⁾			
	Discovery	Matures December 2015			
	&	Interest rate Prime + 6.30% or			
	Development	Floor rate of 9.55%	\$ 10,000	9,862	9,902
Chroma Therapeutics, Ltd. ⁽⁵⁾⁽¹⁰⁾	Drug	Senior Debt			
	Discovery	Matures November 2013			
	&	Interest rate Prime + 7.75% or			
	Development	Floor rate of 12.00%	\$ 4,111	4,718	4,759
Concert Pharmaceuticals, Inc. ⁽⁴⁾	Drug	Senior Debt			
	Discovery	Matures October 2015			
	&	Interest rate Prime + 3.25% or			
	Development	Floor rate of 8.50%	\$ 20,000	19,633	18,983
Coronado BioSciences, Inc. ⁽³⁾	Drug	Senior Debt ⁽¹¹⁾			
	Discovery	Matures March 2016			
	&	Interest rate Prime + 6.00% or			
	Development	Floor rate of 9.25%	\$ 15,000	14,761	14,761
Dicerna Pharmaceuticals, Inc.	Drug	Senior Debt			
	Discovery	Matures January 2015			
	&	Interest rate Prime + 4.40% or			
	Development	Floor rate of 10.15%	\$ 9,166	8,996	8,929
Insmed, Inc.	Drug	Senior Debt ⁽¹¹⁾			
	Discovery	Matures January 2016			
	&	Interest rate Prime + 4.75% or			
	Development	Floor rate of 9.25%	\$ 20,000	19,305	19,674
Merrimack Pharmaceuticals, Inc.	Drug	Senior Debt			
	Discovery	Matures May 2016			
	&	Interest rate Prime + 5.30% or			
	Development	Floor rate of 10.55%	\$ 40,000	39,670	39,670
NeurogesX, Inc. ⁽³⁾	Drug	Senior Debt			
	Discovery	Matures February 2015			
	&	Interest rate Prime + 7.50% or			
	Development	Floor rate of 10.75%	\$ 13,662	13,645	13,884
Paratek Pharmaceuticals, Inc.	Drug	Senior Debt ⁽⁹⁾			
	Discovery	Matures upon liqudation			
	&	Interest rate Fixed 10.00%			
	Development		\$ 45	45	45
		Senior Debt ⁽⁹⁾			
		Matures upon liqudation			
		Interest rate Fixed 10.00%	\$ 36	31	31

Total Paratek Pharmaceuticals, Inc.	76	76
Total Debt Drug Discovery & Development (34.63%)*	177,911	178,675

F-23

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2012

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾
Bridgewave Communications	Communications & Networking	Senior Debt Matures March 2016 Interest rate Prime + 8.75% or Floor rate of 12.00%	\$ 7,500	\$ 7,003	\$ 4,896
OpenPeak, Inc.	Communications & Networking	Senior Debt ⁽¹¹⁾ Matures July 2015 Interest rate Prime + 8.75% or Floor rate of 12.00%	\$ 15,000	15,008	15,158
PeerApp, Inc. ⁽⁴⁾	Communications & Networking	Senior Debt Matures April 2013 Interest rate Prime + 7.50% or Floor rate of 11.50%	\$ 501	588	588
PointOne, Inc.	Communications & Networking	Senior Debt Matures April 2015 Interest rate Libor + 11.00% or Floor rate of 13.50%	\$ 7,000	6,880	6,772
		Senior Debt Matures September 2015 Interest rate Libor + 11.00% or Floor rate of 13.50%	\$ 347	343	333
		Senior Debt Matures December 2016 Interest rate Libor + 11.00% or Floor rate of 13.50%	\$ 3,594	3,594	3,400
Total PointOne, Inc.				10,817	10,505
Total Debt Communications & Networking (6.04	%)*			33,416	31,147
Clustrix, Inc.	Electronics & Computer Hardware	Senior Debt Matures December 2015 Interest rate Prime + 6.50% or	¢		225
Identive Group, Inc.	Electronics & Computer Hardware	Floor rate of 9.75% Senior Debt Matures November 2015 Interest rate Prime + 7.75% or	\$ 235	227	227
		Floor rate 11.00%	\$ 7,500	7,447	7,447
Total Debt Electronics & Computer Hardware (1	.49%)			7,674	7,674
Box, Inc. ⁽⁴⁾	Software	Senior Debt Matures March 2016 Interest rate Prime + 3.75% or		0.010	
		Floor rate of 7.50% Senior Debt Matures July 2014 Interest rate Prime + 5.25% or	\$ 10,000 \$ 1,018	9,910 1,075	9,353 1,060

	Floor rate of 8.50% Senior Debt ⁽¹¹⁾ Matures July 2016 Interest rate Prime + 5.13% or Floor rate of 8.88%	\$ 20,000	20,138	19,274
Total Box, Inc.			31,123	29,687

F-24

Index to Financial Statements

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2012

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Principal Amount	Cost ⁽²⁾	Value ⁽³⁾
Clickfox, Inc.	Software	Senior Debt Matures November 2015 Interest rate Prime + 8.25% or Floor rate of 11.50%	\$ 8,000	\$ 7,318	\$ 7,558
EndPlay,Inc.	Software	Senior Debt Matures August 2015 Interest rate Prime + 7.35% or Floor rate 10.6%	\$ 2,000	1.930	1,930
Hillcrest Laboratories, Inc	Software	Senior Debt Matures July 2015 Interest rate Prime + 7.50% or Floor rate of 10.75%	\$ 4,000	3.923	3,860
JackBe Corporation	Software	Senior Debt Matures January 2016 Interest rate Prime + 7.25% or Floor rate of 10.50%	\$ 3,000	2.900	2,900
Kxen, Inc. ⁽⁴⁾	Software	Senior Debt Matures January 2015 Interest rate Prime + 5.08% or Floor rate of 8.33%	\$ 2.337	2.371	2,192
Tada Innovations, Inc.	Software	Senior Debt ⁽⁹⁾ Matures November 2012 Interest rate Fixed 8.00%	\$ 100	100	_,.,_
Total Debt Software (9.33%)*				49,665	48,127
Althea Technologies, Inc.	Specialty Pharmaceuticals	Senior Debt Matures October 2013 Interest rate Prime + 7.70% or Floor rate of 10.95%	\$ 7,659	7,927	7,927
Quatrx Pharmaceuticals Company	Specialty Pharmaceuticals	Senior Debt ⁽⁹⁾ Matures March 2014 Interest rate Fixed 8.00%	\$ 1,888	1,888	2,394
Total Debt Specialty Pharmaceuticals (2.00%)*				9,815	10,321
Achronix Semiconductor Corporation	Semiconductors	Senior Debt Matures January 2015 Interest rate Prime + 10.60% or Floor rate of 13.85%	\$ 1,847		